An Open Label, Randomized, Cross-Over Study to Investigate the Single Dose Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg) Compared to Lamotrigine Compressed/Standard Tablets (25mg) in Chinese Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Lamotrigine (Primary)
- Indications Bipolar disorders; Epilepsy; Lennox-Gastaut syndrome; Partial epilepsies; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 May 2011 New trial record